The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

aclarubicin     methyl4-[4-dimethylamino-5- [4-hydroxy-6...

Synonyms: SureCN4533, Neuro_000108, STK177207, AKOS005410748, SMP1_000003, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of aclarubicin


High impact information on aclarubicin


Chemical compound and disease context of aclarubicin


Biological context of aclarubicin


Anatomical context of aclarubicin


Associations of aclarubicin with other chemical compounds

  • Both doxorubicin and aclarubicin markedly increased uPA accumulation in RC-K8- and H69-conditioned medium in a dose-dependent manner [23].
  • These results suggest that in vitro resistance to cytarabine, melphalan, etoposide, L-asparaginase, aclarubicin and dexamethasone might represent factors that can predict response to the early course of therapy [24].
  • DMSO-like rapid decrease in c-myc and c-myb mRNA levels and induction of differentiation in HL-60 cells by the anthracycline antitumor antibiotic aclarubicin [13].
  • In the present study we determined the in vitro cross-resistance pattern between DNR, DOX, IDR, ACR and MIT in 48 untreated and 39 relapsed samples from children with ALL using the MTT assay [25].
  • Although the data did not allow firm conclusions to be drawn on the correlation between MDR1 expression and drug resistance towards Ara-C and Mitox, the drug resistance towards Acla clearly was not correlated to, or dependent on, the MDR1 expression level of the AML blast cells [15].

Gene context of aclarubicin


Analytical, diagnostic and therapeutic context of aclarubicin


  1. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Andreassi, C., Jarecki, J., Zhou, J., Coovert, D.D., Monani, U.R., Chen, X., Whitney, M., Pollok, B., Zhang, M., Androphy, E., Burghes, A.H. Hum. Mol. Genet. (2001) [Pubmed]
  2. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Jensen, P.B., Sørensen, B.S., Demant, E.J., Sehested, M., Jensen, P.S., Vindeløv, L., Hansen, H.H. Cancer Res. (1990) [Pubmed]
  3. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Jensen, P.B., Jensen, P.S., Demant, E.J., Friche, E., Sørensen, B.S., Sehested, M., Wassermann, K., Vindeløv, L., Westergaard, O., Hansen, H.H. Cancer Res. (1991) [Pubmed]
  4. Transplantability and sensitivity to natural killer cells of aclarubicin-resistant murine lymphoma. Sugimoto, Y., Hirakawa, Y., Tanaka, N., Tahara, M., Sato, I., Nishimura, T., Suzuki, H., Tanaka, N. Cancer Res. (1986) [Pubmed]
  5. Aclacinomycin A stabilizes topoisomerase I covalent complexes. Nitiss, J.L., Pourquier, P., Pommier, Y. Cancer Res. (1997) [Pubmed]
  6. Stat5 constitutive activation rescues defects in spinal muscular atrophy. Ting, C.H., Lin, C.W., Wen, S.L., Hsieh-Li, H.M., Li, H. Hum. Mol. Genet. (2007) [Pubmed]
  7. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Jensen, P.B., Sørensen, B.S., Sehested, M., Grue, P., Demant, E.J., Hansen, H.H. Cancer Res. (1994) [Pubmed]
  8. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Chen, M., Beck, W.T. Cancer Res. (1993) [Pubmed]
  9. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Jin, J., Jiang, D.Z., Mai, W.Y., Meng, H.T., Qian, W.B., Tong, H.Y., Huang, J., Mao, L.P., Tong, Y., Wang, L., Chen, Z.M., Xu, W.L. Leukemia (2006) [Pubmed]
  10. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. Lu, W., Wan, J., Zhang, Q., She, Z., Jiang, X. Int. J. Cancer (2007) [Pubmed]
  11. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Jensen, P.B., Vindeløv, L., Roed, H., Demant, E.J., Sehested, M., Skovsgaard, T., Hansen, H.H. Br. J. Cancer (1989) [Pubmed]
  12. Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients. Staib, P., Lathan, B., Knöppel-Schwark, S., Tesch, H., Voliotis, D., Steinmetz, H.T., Schwonzen, M., Wickramanayake, P.D., Diehl, V. Ann. Oncol. (1998) [Pubmed]
  13. DMSO-like rapid decrease in c-myc and c-myb mRNA levels and induction of differentiation in HL-60 cells by the anthracycline antitumor antibiotic aclarubicin. Stöcker, U., Schaefer, A., Marquardt, H. Leukemia (1995) [Pubmed]
  14. In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin. Holm, B., Jensen, P.B., Sehested, M., Hansen, H.H. Cancer Chemother. Pharmacol. (1994) [Pubmed]
  15. MDR1 gene expression and drug resistance of AML cells. Nørgaard, J.M., Bukh, A., Langkjer, S.T., Clausen, N., Palshof, T., Hokland, P. Br. J. Haematol. (1998) [Pubmed]
  16. Aclarubicin inhibits phosphatidylinositol hydrolysis and contraction of rat aorta. Wakabayashi, I., Sakamoto, K., Hatake, K., Tanaka, H. Eur. J. Pharmacol. (1994) [Pubmed]
  17. A gene cluster from Streptomyces galilaeus involved in glycosylation of aclarubicin. Räty, K., Kunnari, T., Hakala, J., Mäntsälä, P., Ylihonko, K. Mol. Gen. Genet. (2000) [Pubmed]
  18. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage. Gieseler, F., Bauer, E., Nuessler, V., Clark, M., Valsamas, S. Leukemia (1999) [Pubmed]
  19. Inhibitory effects of aclarubicin on nitric oxide production in aortic smooth muscle cells and macrophages. Wakabayashi, I., Mayer, B., Groschner, K. Biochem. Pharmacol. (2000) [Pubmed]
  20. Alteration of plasma membrane of drug-resistant tumor cells: 230-kilodalton protein identified by monoclonal antibody. Sugimoto, Y., Suzuki, H., Tanaka, N. Biochem. Biophys. Res. Commun. (1983) [Pubmed]
  21. Effect of aclarubicin on contractile response of rat aorta. Wakabayashi, I., Hatake, K., Kakishita, E. Eur. J. Pharmacol. (1989) [Pubmed]
  22. Expression of glutathione S-transferase P1-1 in differentiating K562: role of GATA-1. Schnekenburger, M., Morceau, F., Duvoix, A., Delhalle, S., Trentesaux, C., Dicato, M., Diederich, M. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
  23. Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells. Kiguchi, T., Niiya, K., Shibakura, M., Miyazono, T., Shinagawa, K., Ishimaru, F., Kiura, K., Ikeda, K., Nakata, Y., Harada, M. Int. J. Cancer (2001) [Pubmed]
  24. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Yamada, S., Hongo, T., Okada, S., Watanabe, C., Fujii, Y., Ohzeki, T. Leukemia (2001) [Pubmed]
  25. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Klumper, E., Pieters, R., den Boer, M.L., Huismans, D.R., Loonen, A.H., Veerman, A.J. Br. J. Cancer (1995) [Pubmed]
  26. Phenotypic reversion induced by anthracyclines in ras oncogene-expressed cells; structure-activity relationships. Kanbe, T., Tsuchiya, K.S., Hori, M., Ekimoto, H., Takahashi, Y., Takeuchi, T. Biol. Pharm. Bull. (1994) [Pubmed]
  27. Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16. Petersen, L.N., Jensen, P.B., Sørensen, B.S., Engelholm, S.A., Spang-Thomsen, M. Investigational new drugs. (1994) [Pubmed]
  28. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Lehne, G., De Angelis, P., Clausen, O.P., Rugstad, H.E. Br. J. Cancer (1996) [Pubmed]
  29. Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. Ichihara, T., Sakamoto, K., Mori, K., Akagi, M. Cancer Res. (1989) [Pubmed]
  30. Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone. Yoshida, T., Nakamura, S., Ohtake, S., Kobayashi, K., Kanno, M., Matsuda, T., Matano, S., Kondo, K., Okafuji, K., Kanai, M. Cancer Chemother. Pharmacol. (1989) [Pubmed]
WikiGenes - Universities